Watch NVCR. Know when insiders buy.
One email the day a filing lands. Free.
NVCR
NovoCure Ltd
16.25
−0.28 −1.69%
USD · close Sep 23
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
12
FLAG · shorts 12
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.9BP/E —DIV YIELD —FCF YIELD -1.34%REV TTM $699.2M +11.0%NET INCOME −$148.6MNET DEBT $475.1M52W 10.03 – 19.99SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $183.6M | +15.6% | 77.6% | −$10.6M | −$15.7M | — | -0.13 | $8.1M | $6.9M | $1.2M | Jul 23 |
| Q1 2026 · Mar 31 | $174.1M | +12.3% | 77.6% | −$67.4M | −$71.1M | — | -0.62 | −$13.5M | $5.2M | −$18.7M | Jul 23 |
| Q4 2025 · Dec 31derived | $174.3M | +8.1% | 75.8% | −$40.4M | −$24.5M | — | -0.22 | −$18M | $4.9M | −$22.9M | Jul 23 |
| Q3 2025 · Sep 30 | $167.2M | +7.8% | 73.2% | −$36M | −$37.3M | — | -0.33 | $20.6M | $5.7M | $14.9M | Oct 30 |
| Q2 2025 · Jun 30 | $158.8M | +5.6% | 73.9% | −$39.5M | −$40.1M | — | -0.36 | −$15.9M | $5.5M | −$21.4M | Jul 23 |
| Q1 2025 · Mar 31 | $155M | +11.9% | 75.1% | −$37.9M | −$34.3M | — | -0.31 | −$35.7M | $10.6M | −$46.3M | Jul 23 |
| Q4 2024 · Dec 31derived | $161.3M | +20.5% | 79.2% | −$63.3M | −$65.9M | — | -0.61 | −$3.5M | $8.9M | −$12.4M | Feb 26 |
| Q3 2024 · Sep 30 | $155.1M | +21.8% | 77.2% | −$32.1M | −$30.6M | — | -0.28 | $10.4M | $10.7M | −$307K | Oct 30 |
| Q2 2024 · Jun 30 | $150.4M | — | 77.0% | −$33.6M | −$33.4M | — | -0.31 | −$1.7M | $11.4M | −$13.2M | Oct 30 |
| Q1 2024 · Mar 31 | $138.5M | — | 75.7% | −$41.5M | −$38.8M | — | -0.36 | −$31.6M | $11.8M | −$43.4M | Oct 30 |
| Q4 2023 · Dec 31derived | $133.8M | — | 75.7% | −$51.7M | −$47.1M | — | -0.44 | −$14.6M | $6.8M | −$21.4M | Feb 26 |
| Q3 2023 · Sep 30 | $127.3M | — | 74.8% | −$58.2M | −$49.5M | — | -0.46 | −$19.3M | $7.3M | −$26.6M | Oct 30 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $655.4M | 74.5% | −$153.8M | −$136.2M | -20.8% | -1.22 | −$49M | $26.6M | −$75.7M | — | — |
| FY2024 · to Dec 31 | $605.2M | 77.3% | −$170.5M | −$168.6M | -27.9% | -1.56 | −$26.4M | $42.9M | −$69.2M | — | — |
| FY2023 · to Dec 31 | $509.3M | 74.8% | −$232.9M | −$207M | -40.6% | -1.95 | −$73.3M | $27.1M | −$100.4M | — | — |
| FY2022 · to Dec 31 | $537.8M | 78.6% | −$89.5M | −$92.5M | -17.2% | -0.88 | $30.8M | $21.4M | $9.4M | — | — |
| FY2021 · to Dec 31 | $535M | 78.5% | −$44.3M | −$58.4M | -10.9% | -0.56 | $82.8M | $24.2M | $58.6M | — | — |
| FY2020 · to Dec 31 | $494.4M | 78.5% | $30.4M | $19.8M | 4.0% | 0.18 | $99.1M | $15M | $84.2M | — | — |
Every number comes from NovoCure Ltd's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.